Results 261 to 270 of about 2,170,785 (365)

Randomized Controlled Trial of a Low Animal Protein, High Fiber Diet in the Prevention of Recurrent Calcium Oxalate Kidney Stones [PDF]

, 1996
Robert A. Hiatt, Bruce Ettinger, Bette J. Caan, C. P. Quesenberry, Diane Duncan, John T. Citron   +5 more
openalex   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Leveraging brief video interventions to increase treatment-seeking among depressed youth: a randomized controlled trial. [PDF]

World Psychiatry
Amsalem D, Jankowski SE, Fisch CT, Haim-Nachum S, Markowitz JC, Pope LG, Dixon LB.   +6 more
europepmc   +1 more source

Randomized Controlled Trial of Selective Bowel Decontamination for Prevention of Infections Following Liver Transplantation [PDF]

, 1996
Paul M. Arnow, G. Carandang, Rachel Zabner, Marleen Irwin   +3 more
openalex   +1 more source

Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti‐CGRP Monoclonal Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study assessed whether continued treatment with anti‐CGRP monoclonal antibodies (mAbs) is driven more by reductions in monthly migraine days (MMDs) or patients' global impression of change (PGIC), a patient‐reported outcome. Among 169 patients treated with anti‐CGRP mAbs, 21.3% discontinued due to ineffectiveness. PGIC responders (≥ 5) at
Marina Romozzi, Catello Vollono, Paolo Calabresi, Francesco De Cesaris, Luigi Francesco Iannone   +4 more
wiley   +1 more source

Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial. [PDF]

BMC Med
Wang F, Yang C, Shu Y, Lin CX, Yao Y, Li Y, Zhang YM, Wang X, Meng LQ, Cheng XY, Liu G, Zhao MH, Cui Z.   +12 more
europepmc   +1 more source

Revisiting the Randomized Controlled Trial

Pakistan Journal of Medical Sciences, 2017
openaire   +3 more sources

Interferon alfa in acute posttransfusion hepatitis C: A randomized, controlled trial

, 1992
John B. Gross
openalex   +1 more source

Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial [PDF]

, 1999
Peter Davey, Ann-Marie Craig, Cathy Hau, Mo Malek   +3 more
openalex   +1 more source

Histone Deacetylase 6 Brain PET in Amyotrophic Lateral Sclerosis‐Frontotemporal Spectrum Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective [18F]EKZ‐001 is a positron emission tomography (PET) tracer targeting histone deacetylase 6 (HDAC6), an enzyme responsible for intracellular transport and clearance of misfolded proteins. HDAC6 modulation is a promising treatment strategy in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS).
Greet Vanderlinden, Charles Carron, Donatienne Van Weehaeghe, Joke De Vocht, Fouke Ombelet, Pegah Masrori, Caro De Weerdt, Rebecca E. James, Lauren T. Evans, Frederick A. Schroeder, Jacob M. Hooker, Michel Koole, Janice E. Kranz, Tonya M. Gilbert, Philip Van Damme, Koen Van Laere   +15 more
wiley   +1 more source